Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 5, 2017
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public ...
July 5, 2017
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
June 5, 2017
New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections
NEW ORLEANS, June 03, 2017 (GLOBE NEWSWIRE) -- New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.’s (PRTK) Phase 3 antibiotic ...
June 5, 2017
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
ROCKVILLE, Md., June 04, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
June 5, 2017
Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the appointment of ...
June 5, 2017
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials of Chk1 Inhibitor SRA737
VANCOUVER , June 5, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
June 5, 2017
MediWound to Present at the Jefferies Global Healthcare Conference
YAVNE, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
June 5, 2017
New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM
TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced the presentation of new data demonstrating that treatment with VB-111 (ofranergene ...
June 5, 2017
Achaogen Highlights Data Demonstrating Potential of Plazomicin Against MDR Gram-Negative Bacteria at ASM Microbe 2017 Annual Meeting
NEW ORLEANS, June 05, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today ...
June 5, 2017
Aurinia Presents Additional Data from Phase Iib Aura-Lv Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (AUPH)(AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, presented additional data ...
June 5, 2017
Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting
NEWTOWN, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
June 5, 2017
VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference
VBI Vaccines Inc. (VBIV)(VBV.TO) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, VBI's President and CEO, ...
June 1, 2017
Minerva Announces Amended Agreement for MIN-202 in Insomnia
WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
June 1, 2017
Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference
SAN DIEGO, May 31, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, will present at the 2017 Jefferies Global ...
June 1, 2017
TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York
<b>Leuven (BELGIUM) - June 1, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company </b><b>focused on exploiting the anti-inflammatory ...
June 1, 2017
OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
TAIPEI, Taiwan, June 1, 2017 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPex:4174), announced today an agreement with Threshold Pharmaceuticals, Inc. (THLD) to ...
June 1, 2017
Ignyta to Present at Jefferies 2017 Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, ...
June 1, 2017
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference
RALEIGH, N.C., June 1, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at ...
June 1, 2017
Foamix Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, New Jersey, June 1, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing ...
June 1, 2017
Achaogen Initiates C-Scape Clinical Development Program with Phase 1 Study of Orally-Administered Antibacterial Candidate
SOUTH SAN FRANCISCO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
Page 108 of 117